Weight-Loss drug mounjaro could keep hearts in rhythm after ablation
NCT ID NCT07630454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the diabetes and weight-loss drug tirzepatide (Mounjaro) can reduce the chance of atrial fibrillation coming back after a heart procedure called catheter ablation. About 602 adults with obesity and a type of heart failure (HFpEF) will get either tirzepatide injections plus standard care, or standard care alone, for 12 months. The main goal is to see if tirzepatide lowers the number of people who have another episode of irregular heartbeat.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirzepatide (Mounjaro), a weekly injection for weight and blood sugar control
What this could lead to
If it works, this could point toward a new way to prevent atrial fibrillation from coming back after ablation in people with obesity and heart failure.
What could go wrong
This trial hasn't started yet, and it's open-label, which can bias results. Tirzepatide may cause side effects like nausea or vomiting, and the benefit for heart rhythm is not proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China
Contact Email: •••••@•••••